Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 4/20 | 0.74 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.74 |
| ▸ | MAPT | P10636 | 2/20 | 0.74 |
| ▸ | LMNA | P02545 | 1/20 | 0.74 |
| ▸ | ATM | Q13315 | 1/20 | 0.74 |
| ▸ | HTT | P42858 | 2/20 | 0.69 |
| ▸ | AHR | P35869 | 1/20 | 0.68 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.67 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.67 |
| ▸ | NOTUM | Q6P988 | 1/20 | 0.67 |
| ▸ | NPC1 | O15118 | 3/20 | 0.66 |
| ▸ | RAB9A | P51151 | 3/20 | 0.66 |
| ▸ | DDX3X | O00571 | 2/20 | 0.65 |
| ▸ | IMPDH2 | P12268 | 1/20 | 0.64 |
| ▸ | TSHR | P16473 | 1/20 | 0.58 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.57 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.57 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30051982 | 0.83 | MEN1 (0.77) | MEN1KMT2AMAPTLMNAATM | |
| SCHEMBL9637653 | 0.83 | MEN1 (0.77) | MEN1KMT2AMAPTLMNAATM | |
| SCHEMBL8016258 | 0.83 | NPC1 (0.68) | MEN1KMT2AMAPTLMNAATM | |
| SCHEMBL5950228 | 0.82 | HTT (0.66) | MEN1KMT2AMAPTLMNAATM | |
| SCHEMBL812756 | 0.82 | DDX3X (0.80) | MEN1KMT2AMAPTLMNAHTT | |
| SCHEMBL10665495 | 0.82 | RAB9A (0.79) | MEN1KMT2AMAPTLMNAHTT | |
| SCHEMBL824577 | 0.82 | KMT2A (0.69) | MEN1KMT2AMAPTLMNAATM | |
| SCHEMBL22926342 | 0.82 | HTT (1.00) | MEN1KMT2AMAPTLMNAATM | |
| Bromide SCHEMBL29417998 | 0.82 | MEN1 (0.74) | MEN1KMT2AMAPTLMNAATM | |
| Hydrochloric Acid SCHEMBL29388210 | 0.82 | MEN1 (0.74) | MEN1KMT2AMAPTLMNAATM |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2015136292-A9 | USE OF DDX3X INHIBITORS FOR THE TREATMENT OF PNEUMOVIRUS INFECTIONS | UNIVERSITY OF WARWICK (GB) | 2022-04-21 | — | — | WO | disclosed |
| WO-2015136292-A9 | USE OF DDX3X INHIBITORS FOR THE TREATMENT OF PNEUMOVIRUS INFECTIONS | UNIVERSITY OF WARWICK (GB) | 2022-04-21 | — | — | WO | disclosed |
| US-20210022340-A1 | USE OF PYRIDINE UREA COMPOUND HAVING SNAIL-KILLING ACTIVITY | THE NATIONAL INSTITUTE OF PARASITIC DISEASES, CHINESE CENTER FOR DISEASE CONTROL AND PREVENTION (CN) | 2021-01-28 | — | — | US | disclosed |
| US-9884812-B2 | Use of DDX3X inhibitors for the treatment of pneumovirus infections | UNIVERSITY OF WARWICK (GB) | 2018-02-06 | — | — | US | disclosed |
| US-9884812-B2 | Use of DDX3X inhibitors for the treatment of pneumovirus infections | UNIVERSITY OF WARWICK (GB) | 2018-02-06 | — | — | US | disclosed |
| US-20170166519-A1 | USE OF DDX3X INHIBITORS FOR THE TREATMENT OF PNEUMOVIRUS INFECTIONS | UNIVERSITY OF WARWICK (GB) | 2017-06-15 | — | — | US | disclosed |
| US-20170166519-A1 | USE OF DDX3X INHIBITORS FOR THE TREATMENT OF PNEUMOVIRUS INFECTIONS | UNIVERSITY OF WARWICK (GB) | 2017-06-15 | — | — | US | disclosed |
| EP-3116852-A1 | USE OF DDX3X INHIBITORS FOR THE TREATMENT OF PNEUMOVIRUS INFECTIONS | University of Warwick (GB) | 2017-01-18 | — | — | EP | disclosed |
| WO-2015136292-A1 | USE OF DDX3X INHIBITORS FOR THE TREATMENT OF PNEUMOVIRUS INFECTIONS | UNIVERSITY OF WARWICK (GB) | 2015-09-17 | — | — | WO | disclosed |
| WO-2015136292-A1 | USE OF DDX3X INHIBITORS FOR THE TREATMENT OF PNEUMOVIRUS INFECTIONS | UNIVERSITY OF WARWICK (GB) | 2015-09-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210022340-A1 | USE OF PYRIDINE UREA COMPOUND HAVING SNAIL-KILLING ACTIVITY | SLC14A1, UACA, UROD | MEN1 3057/4885KMT2A 4029/4885MAPT 2676/4885 |
| US-20170166519-A1 | USE OF DDX3X INHIBITORS FOR THE TREATMENT OF PNEUMOVIRUS INFECTIONS | DDX3X, DDX1, DDX5 | MEN1 2244/4885KMT2A 2069/4885MAPT 3569/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.